Latest Amgen Inc. Stories
THOUSAND OAKS, Calif., July 29, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) reported total revenue increased 4 percent during the second quarter of 2011 to $3,959 million versus $3,804 million in the second quarter of 2010.
Study outcomes may also provide future direction for the development of drugs to combat osteoporosis, bone fractures.
Thousand Oaks, Calif.
THOUSAND OAKS, Calif., April 20, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) reported adjusted earnings per share (EPS) of $1.34 for the first quarter of 2011, an increase of 3 percent compared to $1.30 for the first quarter of 2010.
CHICAGO, March 21, 2011 /PRNewswire/ -- Seven Summits Research issues critical PriceWatch Alerts for COP, AMGN, NYX, NTAP, and FL. To see what our analysts have discovered about these stocks read the Seven Summits Strategic Investments' PriceWatch Alerts at http://www.iotogo.com/s/032111A (Note: You may have to copy this link into your browser then press the [ENTER] key.) Today's PriceWatch Alerts cover the following stocks: ConocoPhillips (NYSE: COP), Amgen Inc.
Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the publication of preclinical research in the March 18, 2011 issue of the journal Science regarding the activation of cardiac myosin by an investigational drug candidate, omecamtiv mecarbil, and the potential therapeutic role that this novel mechanism may play for patients with systolic heart failure.
SAN FRANCISCO, Jan. 31, 2011 /PRNewswire/ -- Global Real Estate Consultants has helped Boehringer Ingelheim to strengthen their global presence with a new facility in Fremont.
THOUSAND OAKS, Calif., Jan. 24, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.17 for the fourth quarter of 2010, an increase of 11 percent compared to $1.05 for the fourth quarter of 2009.
THOUSAND OAKS, Calif. and INGELHEIM, Germany, Jan. 18, 2011 /PRNewswire/ -- Amgen Inc.
ORLANDO, Fla., Dec. 5, 2010 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN) today announced the final results from a 5-year open-label extension study investigating the long-term efficacy and safety of NplateÂ® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP).
- totally perplexed and mixed up.